Literature DB >> 29997982

Malignancies after lung transplantation.

Anne Olland1,2, Pierre-Emmanuel Falcoz1,2, Gilbert Massard1,2.   

Abstract

Lung transplantation has become an efficient life-saving treatment for patients with end stage respiratory disease. The increasing good outcome following lung transplantation may be explained by growing experience of transplant teams and availability of potent immunosuppressive drugs. Nevertheless, the latter carries an inherent risk for malignancy besides other common side effects such as systemic hypertension, diabetes and renal dysfunction. Malignancies occur in a smaller proportion of patients but explain for a large proportion of deaths following transplantation. From the first year post-transplantation they will represent the third cause of death with an increasing incidence along post lung transplant survival. In this chapter, we will browse the different types of malignancies arising following lung transplantation. According to the different techniques for lung transplantation, specific types of bronchogenic carcinoma will be described in the explanted lung, in the native lung, and in the graft. Risk factors associated to immunosuppressive therapy, but also to occupational and environmental factors, especially smoking, will be discussed. Eventually, we will strive at integrating recommendations for the treatment of malignancies following lung transplantation.

Entities:  

Keywords:  Lung transplantation; bronchogenic carcinoma; immunosuppressive regimen; malignancies; risk factors

Year:  2018        PMID: 29997982      PMCID: PMC6006071          DOI: 10.21037/jtd.2018.05.34

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  58 in total

Review 1.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Understanding the pathophysiology of the asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Arthur F Gelb; Jay A Nadel
Journal:  J Allergy Clin Immunol       Date:  2015-09       Impact factor: 10.793

3.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure.

Authors:  Roger D Yusen; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel B Goldfarb; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Joseph W Rossano; Josef Stehlik
Journal:  J Heart Lung Transplant       Date:  2015-09-03       Impact factor: 10.247

Review 4.  Does interstitial lung disease predispose to lung cancer?

Authors:  Craig E Daniels; James R Jett
Journal:  Curr Opin Pulm Med       Date:  2005-09       Impact factor: 3.155

5.  Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells.

Authors:  C Ahlers; S Kreideweiss; A Nordheim; A Rühlmann
Journal:  Eur J Biochem       Date:  1999-09

6.  Requirement of the acquired immune system in successful cancer chemotherapy with cis-diamminedichloroplatinum (II) in a syngeneic mouse tumor transplantation model.

Authors:  Keisuke Taniguchi; Hiroshi Nishiura; Tetsuro Yamamoto
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

7.  Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.

Authors:  Fiona O Zwald; Margaret Spratt; Bianca D Lemos; Emir Veledar; Clint Lawrence; George Marshall Lyon; Suephy C Chen
Journal:  Dermatol Surg       Date:  2012-05-02       Impact factor: 3.398

8.  Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells.

Authors:  D E Pritchard; J Singh; D L Carlisle; S R Patierno
Journal:  Carcinogenesis       Date:  2000-11       Impact factor: 4.944

9.  Non-lymphoid cancer after liver transplantation.

Authors:  E E Frezza; J J Fung; D H van Thiel
Journal:  Hepatogastroenterology       Date:  1997 Jul-Aug

Review 10.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

View more
  1 in total

Review 1.  Malignancy after lung transplantation.

Authors:  Osnat Shtraichman; Vivek N Ahya
Journal:  Ann Transl Med       Date:  2020-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.